As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Chimeric antigen receptor (CAR) T cell therapy is undoubtedly leading a revolution in cancer therapy1,2. The recent successes of CAR T cell therapy in fighting hematologic malignancies have led to a tremendous increase of interest in the immunotherapeutic field³. The great potential of genetically modified T cells now even expands into the area of solid tumors and infectious diseases⁴. Currently, the manufacturing process of CAR T cells consists of various complex procedures, is labor intensive, and represents one of the biggest challenges in this area. The CliniMACS Prodigy TCT process provides a unique all-in-one solution to these challenges. With the CliniMACS Prodigy Platform, it is possible to generate gene-modified T cells in a standardized and automated process5. It is a breakthrough in cell manufacturing, and a leap to the next generation.
The CliniMACS Prodigy Platform enables the entire workflow for the manufacture of CAR T cells, from T cell selection and activation, to viral transduction, and cell expansion. All cell processing steps are automated, ensuring a highly reproducible and standardized manufacturing process.
During the T cell transduction process, T cells are first enriched by specific selection and then activated overnight. In the next step T cells are transduced with a lentiviral or gamma-retroviral vector. Subsequently, transduced T cells are expanded to the desired cell number for final cell harvest.
For complete regulatory notices click here.
Related PDFs:
CliniMACS Prodigy T Cell Transduction Process (application sheet)
CliniMACS Prodigy T Cell Transduction Process (brochure)
Simple automated manufacturing of gene-engineered T cells from melanoma and lymphoma patient material for adoptive T cell therapy (scientific poster)
Automated manufacturing of gene-engineered T cells under serum-free conditions (scientific poster)
MACS Handbook:
Magnetic cell separation
Related PDFs:
T Cell TransAct (brochure)
Polyclonal T cell activation and expansion tool for clinical-scale manufacturing of gene-modified T cells (scientific poster)
Safety assessment of MACS GMP T Cell TransAct, a robust and potent polyclonal T cell activation and expansion tool for clinical-scale manufacturing of gene-modified T cells (scientific poster)
Related products:
At the end of the CliniMACS Prodigy TCT Process, the final product is harvested in 100 mL buffer of your choice. CAR T cells are then ready for cryopreservation or direct infusion.
Related documents:
View details
